CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read MoreProgress of CLINUVEL’s DNA Repair Program
CLINUVEL PHARMACEUTICALS LTD today announced that two xeroderma pigmentosum (XP) patients have...
Read MoreChair's Letter to Shareholders
On behalf of the Board, thank you to those shareholders who chose...
Read MoreCLINUVEL Kommuniqué VI
Der letzte Monat war eine tragische Lektion in Bezug auf die Herausforderungen...
Read MoreSCENESSE® as Vitiligo Monotherapy
CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) will be evaluated as a monotherapy in...
Read MoreCLINUVEL Kommuniqué V
CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.
Read MoreCLINUVEL Communiqué V
CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...
Read MoreCLINUVEL’S GROWTH AND EXPANSION - Jefferies London Healthcare Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the 2021 Jefferies...
Read MoreResults of Annual General Meeting 2021
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read MoreCEO's Address - 2021 Annual General Meeting
2021 CLINUVEL Annual General Meeting address from CEO, Dr Philippe Wolgen
Read MoreCLINUVEL Expands Pharmaceutical Portfolio
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders
Read More